Skip to content

Depression research published in 2026

Page 35 of 37: studies 681 to 700 of 725, newest first. Back to the depression overview

Studies

Neural and autonomic regulation during brief mindfulness and relaxation interventions in clinical populations: a multimodal MEG study protocol.

Frontiers in Neuroscience 2026 Sabrina Diny, Fabian Schmidt, Andreas Wutz et al.

Mental disorders pose a major and growing challenge for health care systems worldwide, marked by persistent treatment gaps and limited access to psychotherapeutic care. Mind-body interventions such as mindfulness and relaxation practices are widely used in clinical contexts as low-threshold strategies to support stress regulation and psychological well-being. Despite their broad application,...

Metabolic profiling reveals potential biomarkers and underlying signaling pathways involved in mindfulness-based cognitive therapy-improved adolescent depression symptoms.

EXCLI journal 2026 Chun-Hua Xu, Bi-Lan Zhang, Chun-Lan Guan et al.

Mindfulness-based cognitive therapy (MBCT) demonstrates significant efficacy in improving depressive symptoms and modulating metabolic profiles. However, the specific metabolite biomarkers and metabolic pathways underlying MBCT's therapeutic effects in adolescent depression remain unclear. This study aims to identify potential metabolite biomarkers and metabolic regulation pathways associated...

DOI: 10.17179/excli2025-8918 (opens in new tab) Full text (opens in new tab) Adolescent depression Biomarker Differentially abundant metabolite Metabolic regulation pathway +2

Effects of mindfulness-based stress reduction on levels of depression, anxiety, stress, and hopelessness in parents of children with autism: A randomized controlled trial.

Journal of pediatric nursing 2026 Selverhan Yurttutan, Emine Geçkil

This study aimed to evaluate the effects of a Mindfulness-Based Stress Reduction (MBSR) program on depression, anxiety, stress, and hopelessness among parents of children with autism (Autism Spectrum Disorder [ASD]). A pre-test-post-test, parallel-group randomized controlled trial was conducted in two institutions providing education for children with ASD in Konya, Türkiye. The sample included...

Effectiveness of mindfulness-based stress reduction for depression in post-stroke patients: a systematic review and meta-analysis.

Frontiers in Psychiatry 2026 Ying Sun, Shirong Bo, Yongsheng Li

Depression is a common complication after stroke. Although prior studies suggest that mindfulness-based stress reduction (MBSR) may alleviate depressive symptoms in post-stroke patients, the evidence remains inconclusive. This meta-analysis aimed to synthesize randomized controlled trials (RCTs) to evaluate the effects of MBSR on depressive symptoms after stroke. PubMed, Web of Science, Embase,...

DOI: 10.3389/fpsyt.2026.1809626 (opens in new tab) Full text (opens in new tab) Depressive symptoms Meta-analysis Mindfulness-based stress reduction Stroke +1

Neural mechanisms underlying the depression-reducing effects of mindfulness-based stress reduction in university students: A Rs-fMRI study.

Biological Psychology 2026 Xiaonan Zhan, Huibiao Li, Ke Chen et al.

Depression constitutes a major global public health burden, with university students exhibiting a disproportionately high prevalence of depressive symptoms. Although Mindfulness-Based Stress Reduction (MBSR) has demonstrated efficacy in alleviating depressive symptomatology, its underlying neurobiological mechanisms remain incompletely understood. This randomized controlled trial investigated...

Understanding the Affective and Mental Health Outcomes of Meditation Interventions: The Role of Individual Differences in Self-compassion.

Mindfulness 2026 Manuella B Kury, Barbara L. Fredrickson, Patty van Cappellen et al.

Extensive research documents that mindfulness meditation (MM) and loving-kindness meditation (LKM) have benefits for emotional, social, and mental health outcomes. Despite this work documenting the benefits of meditation practice, research also demonstrates that meditation does not always have equivalent effects for all people. So, who is most likely to benefit from meditation practice? In this...

The lifeworld of people who ruminate: a qualitative phenomenological study.

Frontiers in Psychiatry 2026 Aleš Oblak, Sara Rigler, Nika Kovačič et al.

Ruminations are persistent, repetitive, and often distressing thoughts centered on negative events, mood states, and psychiatric symptoms. Recognized as a maladaptive cognitive process, ruminating contributes to the onset and persistence of psychiatric disorders and is strongly linked to negative emotional states, self-criticism, and suicidality. Despite its clinical significance, a...

DOI: 10.3389/fpsyt.2026.1649971 (opens in new tab) Full text (opens in new tab) Depression Lifeworld analysis Micro-phenomenology Phenomenological psychopathology +2

Depression as inferential rigidity: a meta-abductive account.

Frontiers in Psychology 2026 Jian Sun, Li Jin

Depression is a highly prevalent mental disorder worldwide, and its cognitive rigidity-characterized by persistent negative beliefs resistant to countervailing evidence-remains a critical puzzle in philosophical psychiatry and clinical psychology. Existing theories of abductive reasoning have struggled to explain why similar adversities lead to rigid negative cognition in some individuals but...

DOI: 10.3389/fpsyg.2026.1776494 (opens in new tab) Full text (opens in new tab) Depression Cognitive rigidity Inferential pathology Meta-abduction +2

Rethinking the Treatment-Resistant Depression.

Advances in experimental medicine and biology 2026 Yunfei Tan, Kenji Hashimoto 1 citation

Treatment-resistant depression (TRD) affects about one-third of people with major depression and leads to higher suicide rates, impaired functioning, and increased healthcare use. Originally defined as nonresponse to tricyclic antidepressants, TRD now encompasses inadequate response to multiple antidepressant classes, psychotherapy, and neuromodulation. Inconsistent criteria-varying by agency,...

Association of multimodal analgesic protocol with postpartum depression incidence and sleep quality in high-risk parturients.

Frontiers in Medicine 2026 Hui Zhang, Yan An Jiang, Huajun Fu et al.

Postpartum depression (PPD) affects 10-20% of women after childbirth, with incidence reaching 30-50% in high-risk populations. Acute postoperative pain and sleep disturbance represent modifiable risk factors. This study evaluated whether a multimodal analgesic protocol combining dexmedetomidine and esketamine is associated with reduced PPD incidence in high-risk parturients undergoing cesarean...

DOI: 10.3389/fmed.2026.1828838 (opens in new tab) Full text (opens in new tab) Esketamine Cesarean delivery Dexmedetomidine High-risk parturients +3

Investigation of Esketamine Administration During Surgical Procedures for the Alleviation of Postoperative Anxiety and Depression in Adolescent Patients: A Randomized Controlled Trial.

Drug Design, Development and Therapy 2026 Yanhong Li, Kuangyu Zhao, Peipei Cao et al.

Surgical stress can lead to postoperative anxiety and depression, especially in adolescents. These complications reduce quality of life and increase medical burdens, but perioperative psychological interventions for adolescents are limited, and related mechanisms remain unclear. Esketamine (S-ketamine), an N-methyl-D-aspartate receptor (NMDAR) antagonist, has analgesic, sedative,...

Bolus versus Continuous Infusion of Esketamine for Prevention of Postpartum Depression After Caesarean Delivery: A Randomized, Double-Blind, Controlled Trial.

Drug Design, Development and Therapy 2026 Jie Yang, Qiqi Yan, Ting Zhang et al.

Esketamine is increasingly being applied for preventing postpartum depression (PPD). However, clinical protocols for this application are inconsistent, particularly concerning the route of administration. The aim was to determine whether esketamine bolus administration differed from continuous infusion in terms of preventing PPD. A total of 503 subjects without prenatal depression undergoing...

DOI: 10.2147/dddt.s601347 (opens in new tab) Full text (opens in new tab) Esketamine Administration route Caesarean section Postpartum depression

Next-Generation Pharmacotherapy for Depressive Disorders: From Novel Compounds to Optimized Use of Available Drugs.

Drug Design, Development and Therapy 2026 Fan Bu, Lan Qin, Zhengchi Lou et al.

Depressive disorders remain a major source of disability worldwide, and many patients do not achieve sustained remission despite the availability of multiple antidepressant options. Unmet needs are particularly evident in treatment-resistant depression (TRD) and bipolar depression, where delayed onset of action, incomplete response, relapse, residual functional impairment, and tolerability...

Making sense of desperation for treatment in decisions to use psychedelics for depression and anxiety: A qualitative Subreddit study anticipating clinical challenges.

General Hospital Psychiatry 2026 David T. Kryszajtys, Carol Strike, Brian Rush et al. 1 citation

Some individuals interpret persistent depression and anxiety, alongside the exhaustion of standard treatment options, as leading to a desperate need for relief. While desperation may shape how people assess treatment options, its role in psychedelic self-treatment and its relevance for emerging clinical models of psychedelic treatment remain underexplored. We collected discussion threads from...

Blunted arginine vasopressin secretion in individuals experiencing a major depressive episode with comorbid post-traumatic stress disorder: Results from an exploratory study using copeptin as a surrogate marker.

Journal of Neuroendocrinology 2026 Hiroe Hu, Yoojin Lee, Alaina N Tillman et al. 1 citation

Arginine vasopressin (AVP) modulates stress responsivity and social-affective behaviors, but its role in mood and trauma-related disorders remains poorly defined due to challenges in peripheral measurement. This study used copeptin, a stable, reliable, and well-validated surrogate marker of AVP secretion, to assess vasopressinergic function in a transdiagnostic sample of individuals...

DXM, CYP2D6-inhibiting antidepressants, piracetam, and glutamine: proposing a ketamine-class antidepressant regimen with existing drugs.

Frontiers in Psychiatry 2026 Ngo Cheung 6 citations

Rapid-acting antidepressants show that mood can lift within hours when glutamatergic circuits shift from an "NMDA-dominant" to an "AMPA-dominant" state. Intravenous ketamine achieves this flip but is hampered by dissociation and logistics, while dextromethorphan + bupropion (Auvelity®) primarily supplies the initial NMDA blockade and yields slower, less durable benefit. We hypothesize that a...

Modulation of Magnetic Resonance Spectroscopy Levels of Glutamate and GABA by Ketamine in Treatment-Resistant Depression.

Journal of Neuroscience Research 2026 Stephanie N Njau, Artemis Zavaliangos-Petropulu, Shantanu Joshi et al.

Ketamine has emerged as a highly effective intervention for treatment-resistant depression (TRD). Though it acts as a non-competitive antagonist of excitatory N-methyl-D-aspartate receptors (NMDAR), widely expressed in the brain, including on inhibitory γ-aminobutyric acid (GABA)-ergic cells, the mechanisms of its antidepressant action are less clear. To investigate the links between glutamate...

Ketamine combined with psychotherapy for treatment-resistant depression: Real-world outcomes and the role of subjective experience.

General Hospital Psychiatry 2026 Rebeca Cohen, João Bastos, Catarina Cunha et al. 1 citation

Ketamine, an N-methyl-d-aspartate antagonist, shows promise for treatment-resistant depression (TRD), with psychedelic doses potentially enhancing efficacy. However, its transient antidepressant effects and the need for repeated infusions raise concerns about optimal duration and long-term safety. Two clinical trials have tested the combination of ketamine with psychotherapy for depression,...

Mental health professionals' perspective on the use of esketamine in treatment-resistant depression and their motivation to adopt it: a Saudi cross-sectional study.

Frontiers in Psychiatry 2026 Ahmad H Almadani, Ayedh H Alghamdi, Gosay M Almazyad et al.

Esketamine is an innovative treatment for individuals with treatment-resistant depression (TRD). However, its adoption could depend on the perceptions and motivations of prescribing psychiatrists, among other factors. This study aims to explore the attitudes of psychiatrists (of all levels, including those in training) across Saudi Arabia toward the use of esketamine for TRD and investigate the...

Single low-dose esketamine improves postpartum depression symptoms and recovery quality in cesarean section women.

American Journal of Translational Research 2026 Ran Jing, Yuanyan Tu

To investigate the effects of single low-dose esketamine combined with patient-controlled intravenous analgesia (PCIA) on early postpartum depression symptoms and recovery quality in women undergoing cesarean section. This prospective, randomized, controlled study enrolled 136 women scheduled for elective cesarean section, who were randomly assigned in a 1:1 ratio to the study group (esketamine...

DOI: 10.62347/euok7911 (opens in new tab) Full text (opens in new tab) Esketamine Low dose Cesarean section Patient-controlled intravenous analgesia +1